Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based ca…

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...

Cancer’s Secret Weapon? Scientists Reveal How Tumors “Learn” To Survive Treatment

A newly proposed model suggests cancer cells may resist treatment not just through genetic mutations, but by dynamically ...
GEN

Genetic “Dimmer Switch” Offers Precise Gene Expression Control

Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...
TMCnet

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

LUND, Sweden, April 17, 2026 (GLOBE NEWSWIRE) -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it ...
Forbes

Cancer Breakthrough Reprograms Tumor Immune Cells Directly

Gram-stained section of a macrophage with ingested S epidermidis bacteria, seen as purple granules within its cytoplasm. In this stain, the nucleus appears pale, with a reddish nucleolus. It is ...
Frontiers

Epigenetics mechanism, stress memory, and transgenerational epigenetic inheritance in plant responses to climate-relevant stressors

The field of plant epigenetics is increasingly recognized for its crucial role in mediating plant responses to diverse environmental stressors intensified ...
Medicine Buffalo

Genetic research of reversing aging in adult stem cells and skeletal muscle by a process of cellular reprogramming

CGTE researchers Dr. Stelios Andreadis, center director, and Dr. Kirk Personius are lead co-authors of a paper in the October 24th edition of Nature Communications. This study describes experiments ...

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...